Unknown

Dataset Information

0

Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.


ABSTRACT: Treatment options for patients with hepatocellular carcinoma are rapidly changing based on positive results from phase 3 trials of targeted and immune-based therapies. More agents designed to target specific pathways and immune checkpoints are in clinical development. Some agents have already been shown to improve outcomes of patients with hepatocellular carcinoma, as first- and second-line therapies, and are awaiting approval by the Food and Drug Administration or have been recently approved. We summarize the targeted and immune-based agents in trials of patients with advanced hepatocellular carcinoma and discuss the future of these strategies for liver cancer.

SUBMITTER: Greten TF 

PROVIDER: S-EPMC6340758 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.

Greten Tim F TF   Lai Chunwei Walter CW   Li Guangfu G   Staveley-O'Carroll Kevin F KF  

Gastroenterology 20181001 2


Treatment options for patients with hepatocellular carcinoma are rapidly changing based on positive results from phase 3 trials of targeted and immune-based therapies. More agents designed to target specific pathways and immune checkpoints are in clinical development. Some agents have already been shown to improve outcomes of patients with hepatocellular carcinoma, as first- and second-line therapies, and are awaiting approval by the Food and Drug Administration or have been recently approved. W  ...[more]

Similar Datasets

| S-EPMC7190571 | biostudies-literature
| S-EPMC3682501 | biostudies-literature
| S-EPMC10493094 | biostudies-literature
| S-EPMC7269783 | biostudies-literature
| S-EPMC6780754 | biostudies-literature
| S-EPMC3667684 | biostudies-literature
| S-EPMC5958916 | biostudies-other
| S-EPMC9913568 | biostudies-literature
| S-EPMC8150670 | biostudies-literature
| S-EPMC8422634 | biostudies-literature